Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: The development of a novel prediction formula

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 8, 2012, Pages 744-754

  Saito, K ^a   Katsuno, T ^a   Nakagawa, T ^a   Saito, M ^a   Sazuka, S ^a   Sato, T ^a   Matsumura, T ^a   Arai, M ^a   Miyauchi, H ^a   Matsubara, H ^a   Yokosuka, O ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; INFLIXIMAB; METRONIDAZOLE; PREDNISOLONE; PROTEIN; TACROLIMUS;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CLOSTRIDIUM INFECTION; COLON PERFORATION; COLON RESECTION; DECISION MAKING; DEMOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FACTORIAL ANALYSIS; FEMALE; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERKALEMIA; JAPAN; KIDNEY DYSFUNCTION; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; RELIABILITY; SIDE EFFECT; TERTIARY HEALTH CARE; THROMBOCYTE COUNT; TOXIC MEGACOLON; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866370173     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12033     Document Type: Article

References (31)

1. Dinesen LC, Walsh AJ, Protic MN, et al,. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010; 4: 431-7.
2. Burger DC, Travis S,. Colon salvage therapy for acute severe colitis: cyclosporine or infliximab? Curr Opin Gastroenterol 2011; 27: 358-62.
3. Jarnerot G, Rolny P, Sandberg-Gertzen H,. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ,. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
5. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J,. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24: 319-30.
6. Hart AL, Ng SC,. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment Pharmacol Ther 2010; 32: 615-27.
7. Travis SP, Farrant JM, Ricketts C, et al,. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
8. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI,. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-5.
9. Ho GT, Mowat C, Goddard CJ, et al,. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-87.
10. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ,. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-12.
11. Chang JC, Cohen RD,. Medical management of severe ulcerative colitis. Gastroenterol Clin North Am 2004; 33: 235-50.
12. Carbonnel F, Gargouri D, Lemann M, et al,. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-9.
13. Lichtiger S, Present DH, Kornbluth A, et al,. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.
14. Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J,. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005; 28: 607-14.
15. Campbell S, Travis S, Jewell D,. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005; 17: 79-84.
16. Arts J, D'Haens G, Zeegers M, et al,. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-8.
17. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR,. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000; 95: 2000-8.
18. Cacheux W, Seksik P, Lemann M, et al,. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008; 103: 637-42.
19. Aceituno M, Garcia-Planella E, Heredia C, et al,. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008; 14: 347-52.
20. Huaman Rios JW, Casellas Jorda F, Malagelada Benapres JR,. Predictive factors of poor response to intravenous cyclosporine in steroid-refractory ulcerative colitis. Rev Esp Enferm Dig 2009; 101: 163-71.
21. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
22. Sandborn WJ, van Assche G, Reinisch W, et al,. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
23. Laharie D, Bourreille A, Branche J, et al,. Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: a randomized trial. Gastroenterology 2011; 140: S-112.
24. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A,. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008; 6: 1112-6.
25. Manosa M, Lopez San Roman A, Garcia-Planella E, et al,. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion 2009; 80: 30-5.
26. Leblanc S, Allez M, Seksik P, et al,. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol 2011; 106: 771-7.
27. Chaparro M, Burgueno P, Iglesias E, et al,. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther 2012; 35: 275-83.
28. Lichtiger S, Present DH,. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 16-9.
29. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM,. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993; 88: 640-5.
30. Naganuma M, Ichikawa H, Inoue N, et al,. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 2010; 45: 936-43.
31. Walch A, Meshkat M, Vogelsang H, et al,. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis 2010; 4: 398-404.